Kiora Pharmaceuticals Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia

Reuters

06-03

<a href="https://laohu8.com/S/KPRX">Kiora Pharmaceuticals</a> Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia

Kiora Pharmaceuticals Inc. has announced a strategic partnership with Senju Pharmaceutical Co., Ltd. granting Senju an exclusive option for the development and commercialization of KIO-301, aimed at treating ophthalmic diseases, across key Asian markets including Japan and China. The total potential deal value is estimated to be $110 million, in addition to tiered royalties on sales. Kiora is set to receive an immediate $1.25 million fee for this exclusive option, and should Senju exercise the option, Kiora will obtain a further mid-single digit million up-front payment along with development, regulatory, and commercial milestones. This agreement strengthens Kiora's global commercial reach, complementing their ongoing partnership with Théa outside of Asia, and highlights the demand for innovative treatments for retinal conditions such as retinitis pigmentosa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001372514-25-000050), on June 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540775948"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540775948\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540775948?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540775948","market":"nz","top_or_hot":-1,"title":"Kiora Pharmaceuticals Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KPRX\">Kiora Pharmaceuticals</a> Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kiora Pharmaceuticals Inc. has announced a strategic partnership with Senju Pharmaceutical Co., Ltd. granting Senju an exclusive option for the development and commercialization of KIO-301, aimed at treating ophthalmic diseases, across key Asian markets including Japan and China. The total potential deal value is estimated to be $110 million, in addition to tiered royalties on sales. Kiora is set to receive an immediate $1.25 million fee for this exclusive option, and should Senju exercise the option, Kiora will obtain a further mid-single digit million up-front payment along with development, regulatory, and commercial milestones. This agreement strengthens Kiora's global commercial reach, complementing their ongoing partnership with Théa outside of Asia, and highlights the demand for innovative treatments for retinal conditions such as retinitis pigmentosa.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001372514-25-000050), on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiora Pharmaceuticals Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiora Pharmaceuticals Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-03 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KPRX\">Kiora Pharmaceuticals</a> Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kiora Pharmaceuticals Inc. has announced a strategic partnership with Senju Pharmaceutical Co., Ltd. granting Senju an exclusive option for the development and commercialization of KIO-301, aimed at treating ophthalmic diseases, across key Asian markets including Japan and China. The total potential deal value is estimated to be $110 million, in addition to tiered royalties on sales. Kiora is set to receive an immediate $1.25 million fee for this exclusive option, and should Senju exercise the option, Kiora will obtain a further mid-single digit million up-front payment along with development, regulatory, and commercial milestones. This agreement strengthens Kiora's global commercial reach, complementing their ongoing partnership with Théa outside of Asia, and highlights the demand for innovative treatments for retinal conditions such as retinitis pigmentosa.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001372514-25-000050), on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL45lsGr:1","article_id":"2540775948","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540775948","pubTimestamp":1748948488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kiora Pharmaceuticals Inc. has announced a strategic partnership with Senju Pharmaceutical Co., Ltd. granting Senju an exclusive option for the development and commercialization of KIO-301, aimed at treating ophthalmic diseases, across key Asian markets including Japan and China. The total potential deal value is estimated to be $110 million, in addition to tiered royalties on sales. Kiora is set to receive an immediate $1.25 million fee for this exclusive option, and should Senju exercise the option, Kiora will obtain a further mid-single digit million up-front payment along with development, regulatory, and commercial milestones. This agreement strengthens Kiora's global commercial reach, complementing their ongoing partnership with Théa outside of Asia, and highlights the demand for innovative treatments for retinal conditions such as retinitis pigmentosa.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","KPRX":"Kiora Pharmaceuticals"},"translate_title":"Kiora Pharmaceuticals授予Senju KIO-301眼科治疗在亚洲的独家选择权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPRX":0.9},"content_text":"Kiora Pharmaceuticals Grants Senju Exclusive Option for KIO-301 Ophthalmic Treatment in Asia\n    \n\n        Kiora Pharmaceuticals Inc. has announced a strategic partnership with Senju Pharmaceutical Co., Ltd. granting Senju an exclusive option for the development and commercialization of KIO-301, aimed at treating ophthalmic diseases, across key Asian markets including Japan and China. The total potential deal value is estimated to be $110 million, in addition to tiered royalties on sales. Kiora is set to receive an immediate $1.25 million fee for this exclusive option, and should Senju exercise the option, Kiora will obtain a further mid-single digit million up-front payment along with development, regulatory, and commercial milestones. This agreement strengthens Kiora's global commercial reach, complementing their ongoing partnership with Théa outside of Asia, and highlights the demand for innovative treatments for retinal conditions such as retinitis pigmentosa.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001372514-25-000050), on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}